Foresite Capital Management IV, LLC - Q1 2023 holdings

$193 Million is the total value of Foresite Capital Management IV, LLC's 8 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 0.0% .

 Value Shares↓ Weighting
KNTE  Kinnate Biopharma Inc.$60,447,769
+2.5%
9,671,6430.0%31.36%
+24.5%
PHVS  Pharvaris N.V.$26,153,989
-28.4%
3,246,9260.0%13.57%
-13.0%
LYEL  Lyell Immunopharma, Inc.$23,600,000
-32.0%
10,000,0000.0%12.24%
-17.4%
ACRS  Aclaris Therapeutics, Inc.$22,716,995
-48.6%
2,808,0340.0%11.79%
-37.6%
KURA  Kura Oncology, Inc.$22,624,852
-1.5%
1,849,9470.0%11.74%
+19.7%
SNDX  Syndax Pharmaceuticals, Inc.$18,480,000
-17.0%
875,0000.0%9.59%
+0.8%
CBAY  Cymabay Therapeutics, Inc.$15,583,460
+39.1%
1,787,0940.0%8.09%
+69.0%
QSI  Quantum-Si Incorporated$3,117,398
-3.8%
1,771,2490.0%1.62%
+16.9%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2023-05-12
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
CymaBay Therapeutics, Inc.23Q3 202314.8%
Aclaris Therapeutics, Inc.18Q3 202318.9%
Kura Oncology, Inc.16Q3 202311.7%
Kinnate Biopharma Inc.12Q3 202341.8%
Myokardia, Inc.12Q3 202017.8%
Pharvaris N.V.11Q3 202343.4%
Cytokinetics Incorporated11Q2 202131.6%
Lyell Immunopharma, Inc.10Q3 202329.2%
Insmed Incorporated10Q1 202019.2%
Biohaven Pharmaceutical Holding Company Ltd.9Q1 202014.5%

View Foresite Capital Management IV, LLC's complete holdings history.

Latest filings
TypeFiled
42024-04-05
13F-HR2024-02-13
13F-HR2023-11-13
13F-HR2023-08-11
13F-HR2023-05-12
42023-05-10
42023-02-22
13F-HR2023-02-13
13F-HR2022-11-14
13F-HR2022-08-12

View Foresite Capital Management IV, LLC's complete filings history.

Compare quarters

Export Foresite Capital Management IV, LLC's holdings